|Day Low/High||32.85 / 33.50|
|52 Wk Low/High||29.22 / 69.76|
Nektar, CTC Media upgraged; Brady, Pinnacle West, CNA Surety downgraded.
Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.
The company takes a large charge to leave the inhaled insulin product behind, and earnings plunge.
Emergent BioSolutions gains on a $448 million contract for its anthrax vaccine BioThrax.
Sangamo BioSciences climbs on animal study results for an HIV treatment.
The drugmaker says patients who stop taking inhaled insulin see lung function return to normal in a month.
Its stock will be linked to Exubera's poor launch, at least until some of its other drugs hit the market.
Biotech and pharmaceutical stocks were flat, even with Hologic's $6.2 billion deal for Cytyc.
The company's alcohol-treatment drug did not have the expected impact.
Cramer admits to being wrong on the biopharmaceutical company.
Cramer says mea culpa about not being an NYSE fan and also gets a kick out of the Giants' Jay Feely.
Cramer prefers McDonald's to the Mexican fast-food outfit.
The inhaled insulin will go on sale in September, a few weeks later than planned.
Pfizer and Nektar will know soon enough if diabetics are ready to make the switch from injections to inhaled insulin.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.